Stocks Health care ZNTL
NASDAQ · Health careZentalis Pharmaceuticals, Inc. (ZNTL)
It posted a net loss of $139.5M. In fiscal 2025 capital spending exceeded operating cash flow by $125.2M. At June 30, 2026 it held $24.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Zentalis Pharmaceuticals, Inc. does
Zentalis Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ZNTL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$137.1M | -$1.91 | -$125.2M |
| 2024 | $67.4M | -$165.8M | -$2.33 | -$171.1M |
| 2023 | $0 | -$292.2M | -$4.47 | -$208.4M |
| 2022 | $0 | -$236.8M | -$4.48 | -$166.3M |
| 2021 | n/a | -$158.7M | -$3.72 | -$160.2M |
| 2020 | n/a | -$117.8M | -$4.19 | -$87.6M |
Latest SEC filings
What Zentalis Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 19, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Other event 8-K
- August 14, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- June 18, 2026
- May 27, 2026Additional proxy material DEFA14A
Questions about ZNTL
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ZNTL.
Is Zentalis Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $139.5M.
When did Zentalis Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 19, 2026.
Similar companies
Follow ZNTL
Get an email when Zentalis Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ZNTL: get an email when it filesWhere the numbers come from
Financial figures are the values Zentalis Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.